Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Ovarian Cancer
Related studies linked through entity extraction aliases.
Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Weekly Topotecan Therapy in Patients With Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Gemcitabine in Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
- Status
- COMPLETED
- Phase
- PHASE4
Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse
- Status
- COMPLETED
- Phase
- PHASE2
Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse
- Status
- COMPLETED
- Phase
- PHASE3
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE2
Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
PTEN and IGFBP-3 Correlation in Ovarian Carcinoma Invasion
- Status
- WITHDRAWN
- Phase
- NA
The Assessment of Mesothelin Antigen Specific Immunologic Assays in Ovarian Cancer Patients
- Status
- UNKNOWN
- Phase
- N/A